세계의 항혈소판제 시장(2025-2032년)

The global antiplatelet drugs market reached US$ 2,705.81 million in 2024 and is expected to reach US$ 5.056.03 million by 2032, growing at a CAGR of 8.2 % during the forecast period 2025-2032.

The global antiplatelet drugs market encompasses the pharmaceutical industry segment dedicated to medications that inhibit platelet aggregation, thereby reducing the risk of blood clot formation. These drugs are essential in preventing thrombotic events, such as heart attacks and strokes, particularly among patients with cardiovascular diseases.

Antiplatelet drugs interfere with the activation or aggregation of platelets, which are small cell fragments in the blood that play a crucial role in clot formation. By preventing platelets from clumping together, these medications help maintain normal blood flow and decrease the risk of complications associated with clotting. Common classes of antiplatelet drugs include adenosine diphosphate (ADP) receptor inhibitors and cyclooxygenase inhibitors.

Adenosine diphosphate (ADP) receptor inhibitors in this class include medications such as clopidogrel and ticagrelor, which block ADP receptors on platelets to prevent their activation and aggregation. Cyclooxygenase inhibitors aspirin is a well-known example that inhibits the enzyme responsible for producing thromboxane A2, a potent promoter of platelet aggregation. These factors have driven the global antiplatelet drugs market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases(CVD) is significantly driving the growth of the global antiplatelet drugs market and is expected to drive throughout the market forecast period.

Cardiovascular diseases are the leading cause of mortality worldwide, accounting for approximately 32% of all deaths in 2019, with 17.9 million fatalities attributed to CVDs that year. This alarming statistic underscores the urgent need for effective management strategies, including antiplatelet therapy. As the number of individuals affected by CVD rises, the demand for effective treatments, including antiplatelet medications, correspondingly grows. Projected Increases in CVD Cases.

The rising prevalence of atrial fibrillation (AF) in the United States, Europe, and Asia is expected to significantly boost the global antiplatelet drugs market. According to the National Center for Biotechnology Information (NCBI), a research study published in June 2020 suggests that the number of individuals with AF in the U.S. could reach between 6 to 16 million by 2050, with similar increases anticipated in Europe and Asia.

In Asia alone, projections indicate that 72 million individuals will be diagnosed with AF by 2050. This substantial rise in the patient population will create a burgeoning market for treatments aimed at managing AF. AF is a major risk factor for stroke, with approximately 3 million individuals in Asia expected to experience AF-related strokes by 2050. This increased risk underscores the need for effective antiplatelet therapies to prevent thromboembolic events, driving demand for such medications. All these factors demand the global antiplatelet drugs market.

For these rising numbers of CVDs key players in the industry more focus on the clinical trials, getting positive results, and key initiatives that would prope this antiplatelet drug market growth. For instance, in May 2022, PhaseBio Pharmaceuticals announced the successful completion of a Type B pre-biologics license application (pre-BLA) meeting with the U.S. Food and Drug Administration (FDA) for bentracimab. This development is significant in the context of the global antiplatelet drugs market for several reasons.

Bentracimab is a recombinant human monoclonal antibody fragment specifically designed to reverse the antiplatelet effects of ticagrelor (marketed as Brilinta). Ticagrelor is an oral P2Y12 platelet inhibitor commonly used to prevent blood clots in patients at risk for cardiovascular events. While effective, ticagrelor can increase the risk of bleeding, particularly in emergencies that require urgent surgical intervention or in cases of uncontrolled bleeding. Bentracimab aims to address this issue by rapidly restoring platelet function when necessary.

Moreover, the rising demand for combination therapies contributes to the global antiplatelet drugs market expansion.

Adverse Effects and Contraindications Associated with the Medication

The adverse effects and contraindications associated with the medication will hinder the growth of the global antiplatelet drugs market. The use of antiplatelet drugs is vital in managing cardiovascular conditions, but several adverse effects and contraindications can limit their effectiveness and safety. Understanding these factors is crucial for healthcare providers when prescribing these medications.

Antiplatelet medications are associated with a variety of adverse effects that can impact patient adherence and overall safety issues such as upper gastrointestinal bleeding, nausea, diarrhea, bleeding complications, ecchymosis, hematuria, epistaxis, respiratory effects, ticagrelor-related dyspnea, thrombocytopenia. Common side effects associated with cilostazol include headache, palpitations, arrhythmias, and peripheral edema, all of which can negatively affect a patient's quality of life.

Certain medical conditions and circumstances contraindicate the use of antiplatelet drugs due to an increased risk of serious adverse effects such as Recent Stroke or hemorrhage, major surgery, severe hypertension, end-stage renal disease or decompensated liver cirrhosis, and congestive heart failure.

The adverse effects and contraindications associated with antiplatelet drugs present significant challenges in their use. Healthcare providers must carefully evaluate each patient's medical history and current health status before prescribing these medications to minimize risks and ensure effective management of cardiovascular conditions. Awareness of these factors is critical for optimizing treatment strategies and improving patient outcomes in those requiring antiplatelet therapy. Thus, the above factors could be limiting the global antiplatelet drugs market's potential growth.

For more details on this report - Request for Sample

Segment Analysis

The global antiplatelet drugs market is segmented based on drug class, route of administration, application, distribution channel, and region.

Drug Class:

The adenosine diphosphate (ADP) receptor inhibitors segment is expected to dominate the global antiplatelet drugs market share

The adenosine diphosphate (ADP) receptor inhibitors segment holds a major portion of the global antiplatelet drugs market share and is expected to continue holding a significant portion during the forecast period.

The global antiplatelet drugs market includes a variety of medications designed to inhibit platelet aggregation, thereby preventing thrombotic events, particularly in patients with cardiovascular diseases. A significant segment within this market is comprised of Adenosine Diphosphate (ADP) receptor inhibitors. Key drugs such as clopidogrel, ticagrelor, prasugrel, ticlopidine, and cangrelor.

ADP receptor inhibitors are a class of antiplatelet drugs that function by blocking the P2Y12 receptor on platelets. This blockade prevents the action of adenosine diphosphate (ADP), which is crucial for platelet activation and aggregation. By inhibiting this pathway, these medications significantly reduce the risk of thrombotic events such as heart attacks and strokes.

The demand for ADP receptor inhibitors will continue to rise due to their essential role in managing cardiovascular conditions. Healthcare providers are increasingly adopting combination therapies that incorporate these agents for enhanced efficacy, further propelling market growth.

Furthermore, key players in the industry have innovative product launches and approvals that would propel this segment's growth in the global antiplatelet drugs market. For instance, according to the BioMed Central Ltd research study in January 2024, Ticagrelor is a novel receptor antagonist that selectively binds to the P2Y12 receptor, effectively inhibiting adenosine diphosphate (ADP)-mediated platelet aggregation. Compared to clopidogrel, ticagrelor offers several advantages, including a rapid onset of action, potent effects, and reversible platelet inhibition.

These characteristics make ticagrelor particularly suitable for treating acute coronary syndrome (ACS), especially in cases of acute ST-segment elevation myocardial infarction (STEMI). As a promising option for the effective management of ACS, ticagrelor requires individualized treatment plans tailored to each patient's specific conditions to minimize the risk of serious adverse events.

Also, in February 2021, the European Union approved a new indication for Plavix (clopidogrel), a well-known antiplatelet medication. Plavix (clopidogrel) is an antiplatelet agent that functions by inhibiting the aggregation of platelets, which helps to decrease the risk of blood clot formation. These factors have solidified the segment's global antiplatelet drug market position.

Geographical Analysis

North America is expected to hold a significant position in the global antiplatelet drugs market share

North America holds a substantial position in the global antiplatelet drugs market and is expected to hold most of the market share.

The rising incidence of cardiovascular diseases, including myocardial infarction, stroke, coronary artery disease, and peripheral artery disease, is a major driver for the antiplatelet drugs market. In North America, cardiovascular diseases are among the leading causes of morbidity and mortality, necessitating effective antiplatelet therapies to reduce the risk of thrombotic events.

According to the Centers for Disease Control and Prevention (CDC), in the United States, heart disease remains the leading cause of death, with 702,880 deaths reported in 2022 equivalent to about 1 in every 5 deaths. Additionally, someone experiences a heart attack every 40 seconds, highlighting the critical need for preventive measures and treatments.

The aging population in North America is leading to an increased prevalence of age-related cardiovascular conditions. Older adults are more susceptible to heart diseases, driving the demand for antiplatelet medications as part of their treatment regimen. The demographic shift towards an older population is expected to continue, further increasing the need for effective cardiovascular treatments.

Continuous innovation and development of new antiplatelet agents with improved efficacy and safety profiles are expanding treatment options available to healthcare providers. The introduction of drugs like ticagrelor and prasugrel has enhanced patient outcomes and adherence rates, making these newer agents attractive options in clinical practice.

The North American market has witnessed a rise in regulatory approvals for new antiplatelet drugs and indications. For example, recent approvals for ticagrelor to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA) have broadened its use in clinical practice, thereby driving market growth. The North American market features a diverse array of antiplatelet medications, including aspirin, clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient), and others. This variety allows healthcare providers to tailor treatments according to individual patient needs, further driving market growth.

Furthermore, key players in the industry product launches and approvals that would drive these antiplatelet drugs market growth. For instance, in December 2021, the U.S. Food and Drug Administration (FDA) approved two new indications for XARELTO (rivaroxaban), a medication designed to prevent and treat blood clots, specifically in pediatric patients. XARELTO is an oral anticoagulant that functions by inhibiting Factor Xa, a crucial element in the blood clotting cascade. Thus, the above factors are consolidating the region's position as a dominant force in the global antiplatelet drugs market.

Asia Pacific is growing at the fastest pace in the global antiplatelet drugs market share

Asia Pacific holds the fastest pace in the global antiplatelet drugs market and is expected to hold most of the market share.

The rising incidence of cardiovascular diseases (CVDs), including myocardial infarction, stroke, and peripheral artery disease, is a major driver for the antiplatelet drugs market in the APAC region. As lifestyles change and populations age, the demand for effective antiplatelet therapies to prevent thrombotic events continues to rise.

According to the World Health Organization (WHO), CVDs account for approximately 31% of all global deaths, highlighting the urgent need for effective treatment options. The global population living with heart and circulatory diseases is estimated at around 620 million, with projections indicating significant increases as populations age and lifestyle factors contribute to higher risk. For instance, it is estimated that by 2050, the number of individuals diagnosed with atrial fibrillation (AF) could reach between 6 to 16 million in the U.S. and 72 million in Asia.

The APAC region is witnessing a surge in clinical research activities focused on cardiovascular diseases and antiplatelet therapies. This research not only contributes to better treatment options but also enhances local expertise and innovation within the pharmaceutical industry. According to the National Center for Biotechnology Information (NCBI) research study in January 2025, DT-678 is an innovative antiplatelet prodrug designed to enhance the efficacy of clopidogrel, a widely used antiplatelet medication.

The unique mechanism of DT-678 allows it to release the active metabolite of clopidogrel (known as AM) upon exposure to glutathione, a naturally occurring antioxidant in the body. This study investigates the factors contributing to high on-treatment platelet reactivity (HTPR) observed in patients with acute coronary syndrome (ACS) and evaluates whether DT-678 can effectively overcome this issue.

The aging population in APAC countries, particularly in nations like Japan, China, and India, is contributing to a higher prevalence of age-related cardiovascular conditions. Older adults are more susceptible to heart diseases, which drives the demand for antiplatelet medications as part of their treatment regimen. This demographic shift is expected to increase the burden of CVD significantly over the coming years.

Continuous innovation and development of new antiplatelet agents with improved efficacy and safety profiles are expanding treatment options available to healthcare providers. The introduction of novel drugs and formulations enhances patient outcomes and adherence rates, making them more attractive options for clinicians. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global antiplatelet drugs market.

Competitive Landscape

The major global players in the antiplatelet drugs market include Sanofi, AstraZeneca., Eli Lilly and Company, Chiesi USA, Inc., Healing Pharma India Pvt. Ltd., Taj Pharmaceuticals Limited., Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Boehringer Ingelheim International GmbH, and AdvaCare Pharma among others.

Key Developments

• In August 2022, Bristol Myers Squibb, in collaboration with Janssen Pharmaceuticals, announced results from the Phase 2 AXIOMATIC-SSP dose-ranging study of milvexian, an investigational oral factor XIa (FXIa) inhibitor. This study demonstrated an approximate 30% relative risk reduction in recurrent symptomatic ischemic strokes when milvexian was used in combination with standard antiplatelet therapy compared to placebo. This finding is particularly relevant for patients who have experienced an acute non-cardioembolic ischemic stroke or transient ischemic attack (TIA).

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global antiplatelet drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Application
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Cardiovascular Diseases
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects and Contraindications Associated with the Medication
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 6.1.2. Market Attractiveness Index, By Drug Class
• 6.2. Adenosine Diphosphate (ADP) Receptor Inhibitors*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Clopidogrel
  • 6.2.4. Ticagrelor
  • 6.2.5. Prasugrel
  • 6.2.6. Ticlopidine
  • 6.2.7. Cangrelor
• 6.3. Irreversible Cyclooxygenase (COX) Inhibitors (Aspirin)
• 6.4. Glycoprotein IIb/IIIa Inhibitors
  • 6.4.1. Abciximab
  • 6.4.2. Eptifibatide
  • 6.4.3. Tirofiban
  • 6.4.4. Others
• 6.5. Adenosine Reuptake Inhibitors (Dipyridamole)
• 6.6. Phosphodiesterase Inhibitors (Cilostazol)
• 6.7. Protease-Activated Receptor-1 Antagonists (Vorapaxar)
• 6.8. Thromboxane Inhibitors (Triflusal)

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Parenteral

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Myocardial Infarction*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Percutaneous Coronary Interventions (PCI)
• 8.4. Arterial Thrombosis
• 8.5. Stroke Prevention
• 8.6. Peripheral Artery Disease (PAD)
• 8.7. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Sanofi *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. AstraZeneca.
• 12.3. Eli Lilly and Company
• 12.4. Chiesi USA, Inc.
• 12.5. Healing Pharma India Pvt. Ltd.
• 12.6. Taj Pharmaceuticals Limited.
• 12.7. Merck & Co., Inc.
• 12.8. Otsuka Pharmaceutical Company, Ltd.
• 12.9. Boehringer Ingelheim International GmbH
• 12.10. AdvaCare Pharma

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us